Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17396574 | 0.79 | KDM4E (0.49) | KDM4EALDH1A1MEN1MAPTHPGD | |
| SCHEMBL5936890 | 0.68 | ALDH1A1 (0.64) | KDM4EALDH1A1MEN1MAPTHPGD | |
| SCHEMBL15223583 | 0.68 | ALDH1A1 (0.64) | KDM4EALDH1A1MEN1MAPTHPGD | |
| SCHEMBL4581908 | 0.67 | ABL1 (0.42) | MAPTABL1BCR | |
| SCHEMBL5936773 | 0.67 | ALDH1A1 (0.60) | KDM4EALDH1A1MEN1MAPTHPGD | |
| SCHEMBL17181041 | 0.66 | CDK4 (0.52) | CDK4CCND1CDK6RXFP1KDM4E | |
| SCHEMBL1688454 | 0.66 | ALDH1A1 (0.58) | KDM4EALDH1A1MEN1MAPTHPGD | |
| SCHEMBL19878910 | 0.66 | CDK4 (0.45) | CDK4CCND1CDK6RXFP1KDM4E | |
| SCHEMBL20696704 | 0.65 | ALDH1A1 (0.33) | ALDH1A1MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL12323365 | 0.64 | HTR2C (0.38) | ALDH1A1SMN1; SMN2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10413547-B2 | Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors | G1 THERAPEUTICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10413547-B2 | Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | CDK4 2/4885CCND1 99/4885CDK6 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.